VERTEX PHARMACEUTICALS INC / MA Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $10.19 million as of 2011-03-31, per its 10-Q filed 2011-05-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2011-05-06
- 2011-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $10.19M.
- 2010-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $349.81M.
- 2010-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $53.78M.
- 2010-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $40.02M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2011-03-31 | $10.19M 10-Q · filed 2011-05-06 |
| 2010-12-31 | $349.81M 10-Q · filed 2011-05-06 |
| 2010-09-30 | $53.78M 10-Q · filed 2010-10-28 |
| 2010-06-30 | $40.02M 10-Q · filed 2010-08-03 |
| 2009-12-31 | $340.36M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |